Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update Read more about Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics Read more about Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences Read more about Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences
Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings Read more about Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings
Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. Read more about Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S.
Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children Read more about Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children
Aimmune Therapeutics Announces Second Quarter 2016 Financial Results Read more about Aimmune Therapeutics Announces Second Quarter 2016 Financial Results
Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference Read more about Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer Read more about Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer
Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy Read more about Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy
